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Relation of severe COVID-19 to
polypharmacy and prescribing of
psychotropic drugs: the REACT-SCOT
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Abstract
Background: The objective of this study was to investigate the relation of severe COVID-19 to prior drug prescribing.
Methods: Severe cases were defined by entry to critical care or fatal outcome. For this matched case-control study
(REACT-SCOT), all 4251 cases of severe COVID-19 in Scotland since the start of the epidemic were matched for age, sex
and primary care practice to 36,738 controls from the population register. Records were linked to hospital discharges
since June 2015 and dispensed prescriptions issued in primary care during the last 240 days.
Results: Severe COVID-19 was strongly associated with the number of non-cardiovascular drug classes dispensed.
This association was strongest in those not resident in a care home, in whom the rate ratio (95% CI) associated with
dispensing of 12 or more drug classes versus none was 10.8 (8.8, 13.3), and in those without any of the conditions
designated as conferring increased risk of COVID-19. Of 17 drug classes postulated at the start of the epidemic to be
“medications compromising COVID”, all were associated with increased risk of severe COVID-19 and these associations
were present in those without any of the designated risk conditions. The fraction of cases in the population
attributable to exposure to these drug classes was 38%. The largest effect was for antipsychotic agents: rate ratio 4.18
(3.42, 5.11). Other drug classes with large effects included proton pump inhibitors (rate ratio 2.20 (1.72, 2.83) for = 2
defined daily doses/day), opioids (3.66 (2.68, 5.01) for = 50 mg morphine equivalent/day) and gabapentinoids. These
associations persisted after adjusting for covariates and were stronger with recent than with non-recent exposure.
Conclusions: Severe COVID-19 is associated with polypharmacy and with drugs that cause sedation, respiratory
depression, or dyskinesia; have anticholinergic effects; or affect the gastrointestinal system. These associations are not
easily explained by co-morbidity. Measures to reduce the burden of mortality and morbidity from COVID-19 should
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include reinforcing existing guidance on reducing overprescribing of these drug classes and limiting inappropriate
polypharmacy.
Registration: ENCEPP number EUPAS35558
Keywords: COVID-19, Pharmacoepidemiology, Antipsychotic agents, Opioids, Gabapentinoids, Proton pump
inhibitors, Polypharmacy, Overprescribing
Background
At the start of the COVID-19 epidemic, possible effects
of prior use of medications on the risk of severe disease
were widely discussed. Some of this discussion focused
on drugs suggested to be relevant specifically to SARS-
CoV-2, such as drugs acting on the renin-angiotensin
system [1]. Other discussion focused on drugs associated
with increased risk of community-acquired pneumonia.
A review published on 2 April 2020 listed 17 widely pre-
scribed drug classes associated with increased pneumonia
risk and therefore of concern as “medications compro-
mising COVID” [2]. Excluding immunosuppressive drugs
that are criteria for shielding, this list comprised pro-
ton pump inhibitors, gastrointestinal antispasmodics, H1
antihistamines, hypnotics, sedatives, antipsychotic drugs,
antidepressants, drugs used in nausea and vertigo, opioid
analgesics, gabapentinoids, anti-epileptic drugs, antimus-
carinic drugs used in parkinsonism, urinary antispasmod-
ics and non-steroidal anti-inflammatory drugs.
In initial analysis of a matched case-control study of
risk factors for severe COVID-19 in Scotland (REACT-
SCOT), we reported a strong association of severe
COVID-19 with dispensing of at least one prescription in
the past year [3]. The univariate rate ratios associated with
at least one prescription varied from 3.8 in those aged
under 60 years to 2.3 in those aged 75 years and over.
This association persisted after adjusting for care home
residence, hospital admission in the last 5 years and diag-
noses of conditions designated by public health agencies
as conferring vulnerability to COVID-19 (hereafter listed
conditions). The objective of this study was to investigate
what drug classes underlie this association and whether
any causal effects underlie these associations of severe
COVID-19 with dispensing of prescribed drugs.
Methods
The design of the REACT-SCOT case-control study
has been described in detail elsewhere [3]. A matched
case-control design was chosen to keep computational
requirements within the limits of the resources avail-
able. Record linkage studies using NHS data in Scotland
are governed by the Public Benefit and Privacy Panel
for Health and Social Care which includes patient and
public representatives. All individuals testing positive for
nucleic acid for SARS-CoV-2 in Scotland were ascertained
through the Electronic Communication of Surveillance in
Scotland (ECOSS) database. Admissions to critical care
were obtained from the Scottish Intensive Care Society
and Audit Group (SICSAG) database that captures admis-
sion to all critical care (intensive care or high dependency)
units. Death registrations were obtained from linkage to
the National Register of Scotland. Severe or fatal COVID-
19 was defined as (1) a positive nucleic acid test followed
by entry to critical care or death within 28 days or (2)
a death certificate with COVID-19 as underlying cause.
This definition of severe COVID-19 used for this study
ensures that case ascertainment is not affected by triage
of those assessed as unlikely (on the basis of age and
underlying conditions) to benefit from critical care.
For each case, the Community Health Index database
was used to select up to ten controls matched for sex,
1-year age band, and registered with the same primary
care practice, who were alive and had not yet tested posi-
tive on the date that the case first tested positive.With this
incidence density sampling design, the conditional odds
ratios are interpretable as rate ratios for severe COVID-19
associated with exposure in the population at risk (defined
as all those who have not yet tested positive).
For fatal cases who had not tested positive, the inci-
dent date was assigned as 14 days before death. For this
analysis based on ascertainment of positive test results up
to 6 June 2020, entry to critical care up to 14 June 2020
and deaths up to 12 June 2020, there were 4251 cases and
36,738 controls.
Morbidity and drug prescribing
For all cases and controls, ICD-10 diagnostic codes
were extracted from the last 5 years of hospital dis-
charge records in the ScottishMorbidity Record (SMR01),
excluding records of discharges less than 25 days before
testing positive for SARS-CoV-2, and from the national
cancer registry. Diagnoses of diabetes were extracted
from linkage to the national diabetes register. British
National Formulary (BNF) drug codes for dispensed pre-
scriptions issued in primary care were extracted from the
Scottish Prescribing Information System [4]. A cutoff date
of 15 days before the incident date (date of testing pos-
itive for SARS-CoV-2, or 14 days before death for fatal
cases without a positive test) was set, and prescriptions
dispensed in a 240-day interval before this cutoff date
McKeigue et al. BMCMedicine           (2021) 19:51 Page 3 of 11
were included. For this analysis prescription codes from
BNF chapters 14 and above, comprising dressings, appli-
ances, vaccines, anaesthesia and other preparations were
grouped as “Other”.
We began by testing for association of severe COVID-
19 with the number of drug classes (BNF subparagraph
codes) for which at least one prescription had been dis-
pensed during the period of observation. In accordance
with earlier suggestions that prescribing of multiple car-
diovascular drugs, which is supported by evidence-based
guidelines, should be considered separately from puta-
tively inappropriate polypharmacy [5], we partitioned the
number of drug classes dispensed into cardiovascular and
other drugs. We then undertook a systematic study of
associations will all drug classes and subsequently a test
of the drug classes postulated to be “medications compro-
mising COVID” [2].
For proton pump inhibitors and opioids, it was pos-
sible to use equivalent doses to calculate a total dose
for all drugs in the class. Defined daily doses (DDDs)
of each proton pump inhibitor were obtained from the
DDD/ATC Index of the WHO Collaborating Centre for
Drug Statistics Methodology. Morphine milligram equiv-
alents (MMEs) for opioids were obtained from the website
of the Faculty of Pain Medicine of the Royal College
of Anaesthestists. Average daily doses of proton pump
inhibitors (as DDDs) and opioids (as MME) were calcu-
lated for each individual as the sum of (conversion factor
× strength × quantity dispensed) divided by observation
period. The dose of opioid was calculated as the sum over
opioid-containing items in subparagraph 0407010 (nono-
pioid and compound preparations) and 0407020 (opioid
analgesics).
As described previously, we derived indicator vari-
ables for a list of conditions that have been desig-
nated as risk conditions for COVID-19 by public health
agencies [6]: diabetes, heart disease, asthma or chronic
obstructive airway disease, chronic kidney disease, dis-
abling neurological disease, liver disease and immunod-
eficiency or immunosuppression. ICD-10 diagnostic and
BNF drug codes used to derive these conditions are avail-
able with the ENCEPP registration. Socioeconomic sta-
tus was encoded as the quintile of the postcode-based
Scottish Index of Multiple Deprivation (SIMD).
Statistical analysis
Rate ratios for severe COVID-19 (hereafter COVID-
19) were estimated from conditional logistic regression
models, implemented as Cox regression in the R func-
tion survival::clogit. To estimate the population
attributable fraction—the fraction of cases in the popula-
tion that are attributable to the exposure if the association
between exposure and disease is causal—for a group of
drugs, we fitted a model including these drug classes
together with other covariates and computed the differ-
ence η between the linear predictors from this model with
drug exposures set to their observed values and the linear
predictors from the same model with drug exposures set
to zero. For a rare disease, eη/ (1 + eη) approximates the
population attributable risk fraction [7].
As we had previously shown that care home residence
is associated with a rate ratio of more than 20 for severe
COVID-19, and the profile of prescribing in care home
residents is likely to be different from that in the gen-
eral population, most analyses of the relation of severe
COVID-19 to drug exposure were restricted to those not
resident in a care home.
To control for confounding by co-morbidity, most anal-
yses of association of severe COVID-19 used restriction
to those without any of the designated risk conditions,
rather than adjustment for covariates. The rationale for
this was that electronic health records of drug prescrib-
ing and hospital admissions do not provide information
on the severity of co-morbid conditions, but do contain
enough information to assign the presence or absence of
each of the designated risk conditions. For some specific
drug classes, we were able to define a prespecified list of
relevant covariates.
To distinguish between causality and confounding
as alternative explanations for associations of severe
COVID-19 with drug exposure, we used several further
approaches:
• Testing for consistency of association with drugs that
have a similar mode of action across different
indication groups
• Testing for a dose-response relationship and
stratifying by age group
• Comparison between recent and less recent time
windows of dispensing. Because of limits on the
computational resources available for this study, the
extract of prescription data was limited to
prescriptions encashed from 1 July 2019. An interval
of 240 days, split into two equal windows of 120 days,
was chosen so that there was no left-censoring. The
classic case-crossover design, which compares in
cases only the frequencies of exposure in recent and
nonrecent time windows, can be viewed as a
matched-pairs case-control study in which the case
and control are the same person in recent and
nonrecent time windows [8]. The conditional odds
ratio can thus be estimated as the ratio of number of
cases with recent exposure only to number of cases
with nonrecent exposure only. The analysis that we
report is a refinement of this discordant-pairs ratio
estimate that takes advantage of the availability of a
matched control group. We contrast not the numbers
of cases with recent exposure only and nonrecent
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exposure only, but the conditional odds of case status
between those with recent exposure only and those
with nonrecent exposure only. This controls for any
difference in the population frequencies of exposure
between recent and nonrecent time windows.
Results
Table 1 compares severe non-fatal and fatal cases by
test-positive and entry to critical care. Table 2 shows
frequencies of risk factors in cases and controls by age
group.
Relation of severe COVID-19 to polypharmacy
Figure 1 shows that the rate of severe COVID-19
increased steeply with the number of non-cardiovascular
drug classes and decreased with the number of car-
diovascular drug classes dispensed. Table 3 shows that
this association was restricted to those not resident in a
care home. Among those not resident in a care home,
the association of severe COVID-19 with the number of
non-cardiovascular drug classes dispensed remained after
stratifying by the presence or absence of at least one listed
condition (Supplementary Table S1). This association was
stronger in those aged less than 75 years than in those aged
75 years and over (Supplementary Table S2).
Associations with specific drug classes
Supplementary Table S3 shows that among controls aged
over 75 years dispensed prescriptions of many drug
classes were more frequent in care home residents than in
those living independently. For the next step in the analy-
sis, cases and controls were restricted to those not resident
in a care home. Table 4 shows univariate associations of
dispensing of at least one drug in each BNF subpara-
graph, filtered to show only drug classes with at least
50 exposed individuals and p < 0.001. The drug classes
associated with severe COVID-19 include proton pump
inhibitors, laxatives, multiple classes of drugs acting on
the central nervous system, nutritional supplements and
non-steroidal anti-inflammatory drugs.
Table 5 shows associations of severe COVID-19 with
dispensing of each of the drug classes on the prespecified
list of “medications compromising COVID” [2], restricted
to those not resident in a care home. All drug classes
on this list were associated with increased risk in uni-
variate analyses (though the association with NSAIDS
was stronger in Table 4 where listed conditions were
excluded). This included all the drug classes listed by
Laporte and Healy [2] as having anticholinergic effects
likely to increase risk of pneumonia: H1 antihistamines,
antidepressants, urinary antispasmodics, gastrointestinal
Table 1 Comparison of severe non-fatal and fatal cases, by test-positive status and entry to critical care
Non-fatal Fatal
Test-positive No positive test
Critical care, non-fatal (462) Critical care, fatal (240) No critical care, fatal (2223) No critical care, fatal (1310)
Age [median (IQR)] 59 (50.25–65) 65.5 (58–73) 83 (76–88) 84 (76–89)
Males 305 (66%) 187 (78%) 1111 (50%) 586 (45%)
Care home 4 (1%) 1 (0%) 1051 (47%) 838 (64%)
Any prescription 412 (89%) 223 (93%) 2180 (98%) 1280 (98%)
Any admission 253 (55%) 161 (67%) 1932 (87%) 1092 (83%)
Type 1 diabetes 10 (2%) 2 (1%) 22 (1%) 8 (1%)
Type 2 diabetes 90 (19%) 61 (25%) 503 (23%) 251 (19%)
Other/unknown type 13 (3%) 6 (2%) 22 (1%) 7 (1%)
Ischaemic heart
disease
45 (10%) 31 (13%) 559 (25%) 269 (21%)
Other heart disease 63 (14%) 45 (19%) 1062 (48%) 570 (44%)
Asthma or chronic
airway disease




6 (1%) 5 (2%) 62 (3%) 23 (2%)
Neurological (except
epilepsy) or dementia
20 (4%) 18 (8%) 801 (36%) 542 (41%)
Liver disease 1 (0%) 4 (2%) 30 (1%) 15 (1%)
Immune deficiency or
suppression
5 (1%) 4 (2%) 24 (1%) 6 (0%)
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Table 2 Frequencies of risk factors in cases and controls, by age group







Cases (871) Controls (23,466) Cases (2915)














667 (77%) 16522 (70%) 2507 (86%)













850 (98%) 22885 (98%) 2900 (99%)
Type 1 diabetes 0 (0%) 2 (4%) 46 (1%) 12 (3%) 42 (0%) 8 (1%) 70 (0%) 21 (1%)
Type 2 diabetes 3 (1%) 2 (4%) 246 (6%) 72 (18%) 1305
(15%)
219 (25%) 3970 (17%) 613 (21%)
Other/unknown type 2 (0%) 4 (7%) 22 (1%) 14 (3%) 73 (1%) 8 (1%) 184 (1%) 22 (1%)
Ischaemic heart
disease
2 (0%) 0 (0%) 125 (3%) 33 (8%) 948
(11%)
169 (19%) 4391 (19%) 702 (24%)
Other heart disease 6 (1%) 7 (12%) 174 (4%) 64 (16%) 1225
(14%)
263 (30%) 7190 (31%) 1411 (48%)
Asthma or chronic
airway disease








1 (0%) 0 (0%) 8 (0%) 15 (4%) 30 (0%) 24 (3%) 163 (1%) 57 (2%)
Neurological (except
epilepsy) or dementia
3 (1%) 7 (12%) 60 (1%) 43 (11%) 319 (4%) 177 (20%) 2897 (12%) 1154 (40%)
Liver disease 1 (0%) 0 (0%) 20 (0%) 10 (2%) 52 (1%) 21 (2%) 59 (0%) 20 (1%)
Immune deficiency or
suppression
2 (0%) 1 (2%) 18 (0%) 12 (3%) 47 (1%) 15 (2%) 76 (0%) 11 (0%)
Fig. 1 Rate ratios (with standard errors) in a conditional logistic regression of severe COVID-19 on number of cardiovascular (BNF chapter 4) and
non-cardiovascular drug classes dispensed
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Table 3 Association of severe COVID-19 with number of non-cardiovascular drug classes dispensed, by care home residence
Number of drug classes Controls (36,738) Cases (4251) Rate ratio (95% CI) p value
Not resident in care home (33,803 controls, 2357 cases)
0 4962 (15%) 167 (7%)
1 to 3 11,036 (33%) 442 (19%) 1.56 (1.29, 1.88) 4 × 10−6
4 to 6 8492 (25%) 578 (25%) 2.97 (2.47, 3.59) 4 × 10−30
7 to 9 5083 (15%) 469 (20%) 4.45 (3.66, 5.42) 3 × 10−50
10 to 12 2511 (7%) 328 (14%) 6.6 (5.4, 8.2) 2 × 10−69
>12 1719 (5%) 373 (16%) 10.8 (8.8, 13.3) 5 × 10−110
Care home residents (2935 controls, 1894 cases)
0 40 (1%) 32 (2%)
1 to 3 261 (9%) 167 (9%) 2.01 (0.87, 4.63) 0.1
4 to 6 800 (27%) 395 (21%) 1.38 (0.62, 3.09) 0.4
7 to 9 821 (28%) 574 (30%) 1.86 (0.83, 4.17) 0.1
10 to 12 585 (20%) 425 (22%) 2.02 (0.90, 4.55) 0.09
>12 428 (15%) 301 (16%) 1.91 (0.85, 4.30) 0.1
Table 4 Univariate rate ratios for severe COVID-19 associated with dispensing of each BNF subparagraph code, restricted to those
without a listed condition and not resident in a care home, filtered to show only drug classes with at least 50 exposed individuals and
p < 0.001
BNF subparagraph Controls (17,127) Cases (637) Rate ratio p value
103050: Proton pump inhibitors 4643 228 1.84 (1.51, 2.23) 7 × 10−10
104020: Antimotility drugs 262 20 2.84 (1.60, 5.05) 4 × 10−4
105010: Aminosalicylates 148 15 3.55 (1.83, 6.89) 2 × 10−4
106040: Osmotic laxatives 1251 78 2.33 (1.71, 3.18) 1 × 10−7
401020: Anxiolytics 485 41 2.17 (1.46, 3.23) 1 × 10−4
402010: Antipsychotic drugs 165 25 3.89 (2.29, 6.62) 5 × 10−7
403010: Tricyclic and related antidepressant drugs 1037 64 1.86 (1.36, 2.54) 9 × 10−5
403040: Other antidepressant drugs 498 48 2.74 (1.89, 3.97) 1 × 10−7
407010: Non-opioid analgesics and compound preparations 4202 223 2.05 (1.68, 2.50) 1 × 10−12
407020: Opioid analgesics 1028 79 2.32 (1.72, 3.13) 3 × 10−8
408010: Control of epilepsy 746 51 2.31 (1.63, 3.28) 3 × 10−6
501012: Penicillinase-resistant penicillins 571 41 2.28 (1.53, 3.39) 5 × 10−5
501013: Broad-spectrum penicillins 1155 69 1.92 (1.42, 2.62) 3 × 10−5
603020: Use of corticosteroids 333 33 3.36 (2.11, 5.35) 3 × 10−7
901011: Oral iron 409 26 2.81 (1.66, 4.78) 1 × 10−4
901020: Drugs used in megaloblastic anaemias 1018 56 2.14 (1.51, 3.04) 2 × 10−5
904020: Enteral nutrition 99 17 5.8 (2.7, 12.2) 5 × 10−6
906026: Thiamine hydrochloride (B1) 122 15 3.11 (1.59, 6.07) 9 × 10−4
906040: Vitamin D 1730 73 1.85 (1.33, 2.58) 3 × 10−4
1001010: Non-steroidal anti-inflammatory drugs 1438 86 1.71 (1.31, 2.22) 7 × 10−5
1003020: Rubefacients, topical NSAIDS, capsaicin and poultice 1780 80 1.61 (1.21, 2.14) 1 × 10−3
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Table 5 Associations of severe COVID-19 with drug classes listed by Laporte and Healy (2020), restricted to those not resident in a care
home
Univariate Adjusted
Controls (33,803) Cases (2357) Rate ratio (95% CI) p value Rate ratio (95% CI) p value
103050.Proton pump
inhibitors




1226 (4%) 132 (6%) 1.73 (1.42, 2.10) 3 × 10−8 1.07 (0.87, 1.32) 0.5
304010.Antihistamines 2556 (8%) 263 (11%) 1.61 (1.40, 1.85) 4 × 10−11 1.30 (1.13, 1.51) 4 × 10−4
401010.Hypnotics 1395 (4%) 157 (7%) 1.74 (1.45, 2.09) 2 × 10−9 1.01 (0.83, 1.23) 0.9
401020.Anxiolytics 1308 (4%) 184 (8%) 2.17 (1.83, 2.58) 3 × 10−19 1.25 (1.04, 1.51) 0.02
402010.Antipsychotic
drugs
526 (2%) 151 (6%) 4.18 (3.42, 5.11) 6 × 10−44 2.80 (2.24, 3.51) 2 × 10−19
402030.Drugs used for
mania and hypomania








2913 (9%) 300 (13%) 1.60 (1.40, 1.83) 4 × 10−12 1.18 (1.03, 1.36) 0.02
403040.Other
antidepressant drugs
1561 (5%) 259 (11%) 2.71 (2.34, 3.14) 8 × 10−40 1.76 (1.50, 2.07) 6 × 10−12
406000.Drugs used in
nausea and vertigo
1798 (5%) 213 (9%) 1.95 (1.67, 2.29) 1 × 10−16 1.42 (1.20, 1.68) 4 × 10−5
407020.Opioid
analgesics
3371 (10%) 483 (20%) 2.60 (2.32, 2.92) 1 × 10−59 1.83 (1.61, 2.08) 1 × 10−20
Gabapentinoids 1742 (5%) 253 (11%) 2.29 (1.98, 2.65) 1 × 10−28 1.38 (1.18, 1.62) 8 × 10−5
Other drugs used for
epilepsy













2373 (7%) 206 (9%) 1.17 (1.00, 1.36) 0.05 0.88 (0.75, 1.03) 0.1
Multivariate rate ratios are based on a joint model with all drug classes in the table and SIMD quintile as covariates
antispasmodics, drugs for vertigo, antimuscarinic drugs
used in the treatment of parkinsonism and antiepileptic
drugs. In a conditional logistic regression model with care
home residence as covariate, the fraction of cases of severe
COVID-19 attributable to exposure to drug classes on the
Laporte-Healy list was estimated as 38%.
In a multivariable regression, the strongest independent
associations were with proton pump inhibitors, antihis-
tamines, antipsychotic drugs and opioid analgesics. In
both univariate and multivariable analyses, the highest
rate ratio was that associated with antipsychotic drugs:
univariate rate ratio (95% CI) 4.18 (3.42, 5.11).
As others have noted [2], the chemical structures and
modes of action of drugs used in the treatment of nau-
sea and vertigo overlap with those of antipsychotic drugs.
Supplementary Table S4 shows the univariate associa-
tions of severe COVID-19 with specific drugs classified
in these two subparagraphs of the BNF. Across both
groups of indications, phenothiazines and other drugs
that are dopamine antagonists were strongly associated
with increased rates of severe disease. Rate ratios were ele-
vated both for phenothiazines and for second-generation
antipsychotics: aripiprazole, olanzapine, risperidone and
amrisulpride.
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Time window analyses
Supplementary Table S5 shows for each drug class on
the Laporte-Healy list the rate ratio associated with dis-
pensing in the most recent 120-day time window, with
dispensing only in the previous time window as reference
category. Becausemost users of these drugs had dispensed
prescriptions in both time windows, these analyses are
based on relatively small numbers: the drug classes shown
are restricted to those with at least 500 cases and controls
exposed only in the earlier time window . For all of the
drug classes shown, the rate ratio associated with recent
exposure only is above 1, but only for opioid analgesics
does this association reach stringent levels of statistical
significance.
Dose-response analyses
Supplementary Table S6 shows the relationship of severe
COVID-19 to average daily doses of opioids (as MME)
and proton pump inhibitors (as DDDs) over the 240-day
observation period. For both these drug classes, there
were dose-response relationships, and for proton pump
inhibitors, this relationship was strongest in those aged
less than 75 years. With unexposed as baseline, the uni-
variate rate ratio associated with opioid use in this age
group was 3.66 (2.68, 5.01) in those with average daily
dose of more than 50 mg morphine equivalent (MME),
reduced to 2.96 (2.08, 4.20) on adjusting for care home
residence, SIMD quintile and any history of neoplasm.
For proton pump inhibitors, the univariate rate ratio asso-
ciated with average dose of 2 or more DDDs/day was
2.20 (1.72, 2.83), reduced to 1.99 (1.51, 2.62) by adjusting
for care home residence, SIMD quintile, any diagnosis of
ICD-10 codes K20-K31 (diseases of oesophagus, stomach
and duodenum), non-steroidal anti-inflammatory drugs,
anti-platelet agents and anticoagulants.
Associations with other drug classes
Supplementary Tables S7 and S8 show associations with
drug classes in BNF chapters 2 (cardiovascular) and 10
(musculoskeletal). These chapters were selected as of
interest because specific hypotheses about possible effects
of drugs in these chapters—ACE inhibitors [9], antico-
agulants [10] and hydroxychloroquine [11]—have been
proposed or discussed.
Table S7 shows associations with drugs for the car-
diovascular system. Prescriptions of loop diuretics and
anticoagulants were associated with elevated rate ratios
for severe COVID-19 in univariate andmultivariate analy-
ses. Over all age groups combined, the univariate rate ratio
associated with oral anticoagulants was reduced from 1.87
(1.65, 2.11) to 1.27 (1.11, 1.45) by adjustment for ischaemic
heart disease, other heart disease and ever-use of a proton
pump inhibitor. Of drug classes commonly used to treat
hypertension, ACE inhibitors and angiotensin II receptor
antagonists were associated with reduced risk of COVID-
19.
Supplementary Table S8 shows associations with drugs
for the musculoskeletal system disaggregated by generic
name, as the BNF groups all disease-modifying antirheu-
matic drugs under a single subparagraph code. All anti-
rheumatic drugs were associated with elevated rate ratios
for COVID-19. The univariate rate ratio associated with
hydroxychloroquine sulfate was adjusted for ever-use of a
proton pump inhibitor reducing this to 1.82 (1.16, 2.85).
Discussion
We have shown that severe COVID-19 is associated with
polypharmacy, defined by the number of drug classes dis-
pensed during the period of observation, in individuals
without conditions designated as conferring high risk.
The rate ratios of 5 to 7 associated with dispensing of
more than 10 drug classes are larger than the ratio of
about 2 for all-cause mortality associated with this level
of polypharmacy in a systematic review [12]. Attempt-
ing to investigate associations with specific drugs with
a hypothesis-free approach is difficult because many of
the drug classes that are strongly associated with severe
COVID-19, such as proton pump inhibitors, opioids and
gabapentinoids, are indicators of overprescribing, recog-
nized as such in the Scottish National Therapeutic Index
of prescribing quality [13].
To narrow the hypothesis space, we tested a pre-specified
list of drugs postulated at the start of the epidemic to
increase risk of severe COVID-19, based on previously
described associations with pneumonia or activity on rel-
evant pathways, especially anticholinergic agents [2]. We
have shown that all the drugs originally listed are asso-
ciated with increased risk, but the strongest associations
are with antipsychotic drugs. The dose-response relation-
ship of opioid use to COVID-19 is similar in magnitude
to that reported for community-acquired pneumonia in
a study of people receiving medical care through the
Veterans Administration from 2000–2012 [14]. Although
gabapentinoids are classified in the BNF under subpara-
graph 0408010 (“Control of epilepsy”), in Scotland, they
are widely used in combination with or as substitutes for
opioid analgesics.
In observational studies based on electronic health
records, distinguishing between causality and confound-
ing as possible explanations for associations of adverse
outcomes with drug exposure is challenging because such
associations are confounded by the indications for which
the drugs were prescribed (co-morbidities). Because the
severity of these co-morbid conditions cannot usually be
assessed accurately using electronic health records, con-
trol of confounding based on adjustment for baseline
covariates is likely to be inadequate. We have used several
approaches to overcome this limitation.
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First, we have examined associations between drug
exposure and severe COVID-19 after restricting to
those not diagnosed with designated risk conditions for
COVID-19; this makes it unnecessary to adjust for the
severity of these co-morbid conditions. This use of restric-
tion as a technique to assess evidence for causality does
not affect the generalizability of the association of severe
COVID-19 with polypharmacy, as this association is
present in those with and without risk conditions. Where
exposure-outcome associations are stronger in younger
than in older individuals, as for opioids and proton pump
inhibitors, this favours causality over confounding by co-
morbidity as these co-morbid conditions are less common
at younger ages.
Second, we have used time-window analyses, in which
the comparison is restricted to ever-exposed individu-
als and the rate ratios associated with use only in a
recent time window are compared with rate ratios asso-
ciated with use only in a non-recent time window. Such
“self-controlled” designs, which eliminate confounding by
time-invariant factors are a standard method in pharma-
coepidemiology [15]. We have shown that among ever-
exposed individuals the rate ratios associated with dis-
pensing only in the most recent time window were higher
than the rate ratios associated with dispensing only in an
earlier time window.
Third, we have examined dose-response relation-
ships for two drug classes—opioids and proton pump
inhibitors—where it is possible to standardize dosages
across different drugs in the same class. We have shown
strong dose-response relationships of COVID-19 to dis-
pensed average daily dose. Adjustment for covariates pre-
specified as likely to confound these associations reduces
the effect size only slightly.
Fourth, we can examine whether exposure-outcome
associations are consistent for pharmacologically similar
drugs that are prescribed for different indications. We
have shown that the associations of severe COVID-19
with phenothiazines and other dopamine antagonists are
similar whether these drugs are prescribed as antipsy-
chotic agents or as drugs for nausea and vomiting. As
these two indications are unrelated and there is no obvi-
ous prior hypothesis that they would both predispose
to severe COVID-19, this result favours causality over
confounding by indication. As the rate ratio of 4.2 asso-
ciated with use of antipsychotic agents is larger than the
rate ratios of about 2 associated with common risk con-
ditions such as type 2 diabetes and heart disease that
we have previously reported from this case-control study
[3], it is unlikely that underdiagnosis of these risk con-
ditions in users of antipsychotic agents can explain this
association.
A limitation of this study is that we do not have mor-
bidity data from primary care, which would include risk
factors such as smoking and coding of presenting com-
plaints. Another limitation is that it is not yet possible
in Scotland to capture hospital prescribing data which
includes biologic agents that have immunosuppressive
effects. Strengths of this study are that diagnoses are
based on hospital discharge records coded to ICD-10
(rather than the SNOMED-CT codes used in primary
care databases), and that drug exposure is based on dis-
pensed rather than issued prescriptions. A report from the
Swedish National Public Health Agency that compared
prior drug prescribing rates in fatal cases of COVID-
19 and with prescribing rates in the general population
showed a similar pattern of drug classes associated with
fatal disease, including antipsychotics, opioids and drugs
for gastroesophageal reflux but did not include any con-
trol for covariates [16].
The mechanisms postulated by Laporte and Healy for
drugs to increase risk of severe COVID-19 include seda-
tion, respiratory depression, respiratory dyskinesia and
anticholinergic effects [2]. Dose-response relationships
to risk of community-acquired pneumonia have been
reported for opioids [17] and for antipsychotic drugs
[18]. For proton pump inhibitors, association with risk of
community-acquired pneumonia for recent but not long-
term use has been reported in a large study [19]. However
as SARS-CoV-2 is at least partly an enteric infection
[20] and the ACE2 receptor is expressed in the intes-
tine, it is plausible that proton pump inhibitors and other
drugs acting on the gastrointestinal tract could increase
susceptibility to severe COVID-19 even if they do not
increase risk of pneumonia caused by other infectious
agents. In Scotland, overprescribing is monitored and to
some extent controlled through the National Prescrib-
ing Quality Initiative. It may be relevant to investigate
associations of COVID-19 with drug prescribing in other
countries where COVID-19 epidemics have been espe-
cially severe and overprescribing of drug classes such as
proton pump inhibitors [21–23] or opioids [24] has been
reported previously.
We emphasize that because of the relationship of
COVID-19 to polypharmacy, associations with specific
drug classes cannot be studied without taking into
account how those drug classes are related to the pro-
file of drug prescribing. Of those drug classes that are
not on the Laporte-Healy list, there are strong univari-
ate associations of severe COVID-10 with dispensing of
antibiotics, laxatives and nutritional supplements. The
associations with nutritional supplements are likely to be
confounded by overprescribing. For ACE inhibitors and
angiotensin-II receptor blockers, our results are consis-
tent with other studies that have found no increased risk
associated with these drugs [9, 25] and indeed suggest
some protective effect may be possible. To explore this
more fully will require access to other datasets where
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measurements of blood pressure and other covariates
are available. The relation of prior anticoagulant use to
COVID-19 is of interest because coagulopathy is a feature
of severe disease [10]. Although in this study anticoag-
ulants were associated with increased risk in univari-
ate analysis, this association was reduced by adjusting
for covariates including diagnosed heart disease and co-
prescribing of proton pump inhibitors. Associations with
disease-modifying antirheumatic drugs such as hydroxy-
chloroquine are likely to be confounded by hospital-based
prescribing of biologic anti-rheumatic drugs, which is not
captured by record linkage in Scotland.
Conclusion
Severe COVID-19 is strongly associated with polyphar-
macy in those not resident in a care home. This asso-
ciation is not easily explained by co-morbidity, and it is
strongest in those without hospital diagnoses of condi-
tions that confer high risk of disease. As a prediction of
which drug classes would be associated with increased
susceptibility to severe COVID-19, the Laporte-Healy list
prepared at the start of the epidemic appears to be remark-
ably accurate. Many of the drug classes on this list are rec-
ognized indicators of overprescribing. The consistency of
associations with drugs that have similar modes of action
across different groups of indication, the dose-response
and time window effects support causal explanations for
at least some of these associations. We recommend that
public health agencies should reinforce existing guidelines
on avoidance of overprescribing of these drug classes and
more generally on inappropriate polypharmacy.
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